Novavax likely to come up with COVID vaccine targeting Omicron in Q4
New Delhi: Novavax Inc said on Friday it expects to provide a COVID-19 vaccine targeting Omicron in the fourth quarter as it accelerates development of shots to protect against the BA.4 and BA.5 subvariants.
The U.S. FDA on Thursday recommended COVID-19 vaccine manufacturers change the design of their booster shots beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants.
Novavax expects additional preclinical data on shots tailored against the fast-spreading Omicron subvariants in late summer or fall.
The company's vaccine, based on an earlier strain of the virus, has not yet been authorized in the United States and is currently under U.S. Food and Drug Administration review.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.